Artal Group’s aTyr Pharma ATYR Stock Holding History

Artal Group’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-35,714	Closed	-$406K	–	118
2018 Q3	$406K	Hold	35,714	–	–	0.01%	104
2018 Q2	$455K	Hold	35,714	–	–	0.01%	102
2018 Q1	$1.32M	Hold	35,714	–	–	0.02%	99
2017 Q4	$1.75M	Buy	35,714 +17,857	+100%	+$1.1M	0.03%	99
2017 Q3	$1.26M	Buy	+17,857	New	+$827K	0.02%	102

Other funds holding ATYR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GHCM

Glen Harbor Capital Management San Diego, California $4.82B AUM 4.69% 1-Year Est. Return

MCIM

Meadow Creek Investment Management Atlanta, Georgia $5.09B AUM 5.82% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Artal Group's ATYR Position: Q4 2018 in Review

Artal Group sold out of aTyr Pharma (ATYR) in Q4 2018, closing a stake of 35,714 shares — an estimated $406K sold.

Artal Group first reported a position in ATYR in Q3 2017 and held it in 5 quarters. The position peaked at $1.75M in Q4 2017. 29 funds tracked by Wall St. Rank hold ATYR as of Q4 2018.

Artal Group reported no remaining aTyr Pharma position as of Q4 2018 after selling out during the quarter.
Artal Group sold 35,714 aTyr Pharma shares in Q4 2018, an estimated $406K.
Artal Group first reported a position in aTyr Pharma in Q3 2017 and held it in 5 quarters.
Artal Group's aTyr Pharma position peaked at $1.75M in Q4 2017.
29 funds tracked by Wall St. Rank held aTyr Pharma as of Q4 2018.

Based on Artal Group's 13F filing for Q4 2018, filed 11 Feb 2019.